

Supplementary Table 1. Characteristics of disease flares requiring treatment of 1377 patients with RMD from D1 to 1-month post D-2 following two-dose SARS-CoV-2 mRNA vaccination

N	1377
Flare since D1, no. (%)	151 (11)
Flare between doses	61 (4)
Days from D1 and flare, median (IQR)	5 (2, 12)
Flare after D2	90 (7)
Days from D2 and flare, median (IQR)	11 (3, 20)
Length of flare symptoms (days), median (IQR)	10 (6, 22)
Flare treatment, no. (%)¹	
NSAID	50 (4)
Topical corticosteroid	12 (1)
Oral corticosteroid	114 (8)
Length of treatment in days, median (IQR)	7 (6, 12)
Intramuscular corticosteroid	4 (0.3)
Intravenous corticosteroid	0(0)
Immunomodulatory ²	0 (0)
Hospitalized, no. (%)	0(0)
ICU stay, no. (%)	0 (0)
Baseline immunosuppression changed because of flare, no. (%)¹	35 (3)
Therapy added ¹	21 (2)
Conventional DMARD ³	10 (1)
Biologic ⁴	6 (0.4)
Corticosteroid ⁵	7 (1)
Immunomodulatory ²	0 (0)
Dose increased ¹	23 (2)
Conventional DMARD ⁶	8 (1)
Biologic ⁷	3 (0.2)
Corticosteroid ⁵	12 (1)
Immunomodulatory ²	0 (0)

¹ Participants could select multiple options for these questions so the sum is greater than the N

² Intravenous immunoglobulin (IVIg) or subcutaneous immunoglobulin (SCIg)

³ Hydroxychloroquine, leflunomide, and methotrexate

⁴ Adalimumab, etanercept, rituximab, upadacitinib, secukinumab

⁵ Prednisone and prednisone equivalents

⁶ Hydroxychloroquine, leflunomide, and methotrexate

⁷ Adalimumab, etanercept, secukinumab